Daniel Storey, MD
Family Medicine · Avon, INNPI 1215252754
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Eli Lilly at 56.3% of the total. Reporting peaked in 2024 at $1,934 and has fallen 98.4% since, to $32 in 2025.
Across 130 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- Novo Nordisk$216
- AstraZeneca$194
- AbbVie$153
- Exact Sciences$117
- Amgen$80
- plus $687 from 23 others
Across 191 payments — averaging $4992.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$566K
- AbbVie$277K
- Pfizer$38K
- AstraZeneca$34K
- Boehringer Ingelheim$15K
- Astrazeneca UK Limited$12K
- plus $12K from 2 others
What the payments were for
- Travel & lodging$1,46444%
- Food & beverage$1,84456%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 19 | $1,867 |
| Novo Nordisk | 23 | $216 |
| AstraZeneca | 13 | $194 |
| AbbVie(2 entities) | 10 | $153 |
| Exact Sciences | 7 | $117 |
| Amgen | 5 | $80 |
| Pfizer | 12 | $78 |
| Novartis | 5 | $75 |
| GSK | 4 | $70 |
| Johnson & Johnson | 3 | $53 |
| Eisai Inc. | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Livanova USA, Inc. | 3 | $39 |
| Lilly USA, LLC | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Medtronic | 2 | $22 |
| Nalpropion Pharmaceuticals LLC | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Sanofi | 1 | $19 |
| Acorda Therapeutics, Inc | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
How this compares
$3,314 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $125,626 |
| EliquisApixaban | 105 | $99,119 |
| JardianceEmpagliflozin | 54 | $50,728 |
| MounjaroTirzepatide | 47 | $48,594 |
| JanuviaSitagliptin Phosphate | 26 | $38,874 |
| TrulicityDulaglutide | 27 | $29,663 |
| XareltoRivaroxaban | 23 | $26,052 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $24,089 |
| LinzessLinaclotide | 16 | $21,222 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $15,357 |
| MyrbetriqMirabegron | 21 | $13,625 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $13,251 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $10,965 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 361 | $9,831 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $216 | $125,626116 claims |
| PfizerEliquis | $78 | $99,119105 claims |
| Lilly USA, LLCMounjaro, Trulicity | $38 | $78,25874 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $11 | $71,09286 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Shingrix | $70 | $57,57291 claims |
| Johnson & JohnsonXarelto | $53 | $26,05223 claims |
| AbbVieLinzess | $153 | $21,22216 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $13,62521 claims |
| AstraZenecaSymbicort | $194 | $5,28619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Avon
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.